Drug General Information (ID: DDIVQX50G4)
Drug Name			Tirofiban		Drug Info		Defibrotide		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Fibrinolytic Agents				Antiviral Agents
Structure

Mechanism of Tirofiban-Defibrotide Interaction (Severity Level: Major)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Tirofiban				Defibrotide
Mechanism		Risk of bleeding Antiplatelet				Risk of bleeding Anticoagulant
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Tirofiban and Defibrotide

Recommended Action
Management		Concomitant use of medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with defibrotide. Close clinical and laboratory observation for bleeding complications is recommended during therapy. If bleeding develops, defibrotide should be discontinued and treatment/supportive care provided until the bleeding stops.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Product Information. Defitelio (defibrotide). Jazz Pharmaceuticals, Palo Alto, CA.